Q2 EPS Estimate for Oncobiologics Lowered by Analyst

Oncobiologics, Inc. (NASDAQ:OTLK) – Brookline Capital Acquisition decreased their Q2 2026 earnings per share estimates for Oncobiologics in a report released on Tuesday, February 17th. Brookline Capital Acquisition analyst K. Dolliver now forecasts that the company will post earnings per share of ($0.18) for the quarter, down from their previous estimate of ($0.16). The consensus estimate for Oncobiologics’ current full-year earnings is ($2.27) per share. Brookline Capital Acquisition also issued estimates for Oncobiologics’ Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.18) EPS, FY2026 earnings at ($0.79) EPS and FY2027 earnings at ($0.20) EPS.

OTLK has been the subject of several other research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Oncobiologics in a research note on Monday, December 29th. HC Wainwright restated a “neutral” rating on shares of Oncobiologics in a report on Wednesday. Wall Street Zen lowered Oncobiologics from a “hold” rating to a “sell” rating in a research report on Saturday, January 3rd. Chardan Capital reaffirmed a “neutral” rating on shares of Oncobiologics in a report on Wednesday. Finally, Ascendiant Capital Markets upped their price target on Oncobiologics from $8.00 to $10.00 and gave the company a “buy” rating in a research report on Monday, December 22nd. One research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $6.50.

Oncobiologics Price Performance

NASDAQ:OTLK opened at $0.41 on Friday. Oncobiologics has a one year low of $0.38 and a one year high of $3.39. The company has a market cap of $34.32 million, a PE ratio of -0.16 and a beta of 0.10. The firm’s 50 day simple moving average is $0.90 and its 200 day simple moving average is $1.31.

Oncobiologics (NASDAQ:OTLK) last released its quarterly earnings results on Tuesday, February 17th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.05). The firm had revenue of ($1.21) million during the quarter, compared to the consensus estimate of $3.14 million.

Institutional Trading of Oncobiologics

Large investors have recently bought and sold shares of the business. Russell Investments Group Ltd. lifted its stake in shares of Oncobiologics by 865.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock valued at $39,000 after purchasing an additional 21,941 shares during the period. AQR Capital Management LLC increased its holdings in Oncobiologics by 42.7% in the first quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock worth $103,000 after purchasing an additional 25,351 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in Oncobiologics by 74.1% in the first quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock worth $126,000 after purchasing an additional 44,063 shares in the last quarter. 11.20% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Oncobiologics

Here are the key news stories impacting Oncobiologics this week:

• Positive Sentiment: Brookline Capital Acquisition raised its Q4 2026 EPS estimate for OTLK to ($0.18) from ($0.22), narrowing the expected quarterly loss — a modest positive signal that one shop sees slightly better near-term performance.
• Neutral Sentiment: HC Wainwright reiterated a “Neutral” rating on Oncobiologics while publishing updated quarterly/annual estimates; the firm remains cautious but did not upgrade or downgrade the stock. HC Wainwright Reaffirms “Neutral” Rating for Oncobiologics (NASDAQ:OTLK)
• Neutral Sentiment: Chardan Capital reiterated its “Neutral” rating on OTLK, signaling no near-term change in analyst stance despite the earnings miss and estimate revisions. Chardan Capital Reiterates Neutral Rating for Oncobiologics (NASDAQ:OTLK)
• Negative Sentiment: HC Wainwright cut FY2026 estimates significantly (FY2026 EPS to ($0.42) from ($0.28)) and trimmed FY2027 to ($0.21) from ($0.19), and nudged Q4 2026 to a larger expected loss — these downward revisions signal weaker near-term profitability expectations and add selling pressure.
• Negative Sentiment: Brookline Capital Acquisition lowered multiple 2026 quarterly and full‑year EPS forecasts (e.g., FY2026 now ($0.79) vs. prior ($0.74); Q2/Q3 2026 also reduced), indicating broader analyst downside revisions across the board.
• Negative Sentiment: Oncobiologics’ recent reported miss (Feb. 17: EPS ($0.22) vs est. ($0.17); revenue sharply below expectations) remains the primary near-term catalyst weighing on the stock—analyst cuts followed the miss and are likely driving continued downward price pressure.

About Oncobiologics

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.